The CEO's Conviction $RGC
Regencell Bioscience Holdings (RGC), a healthcare bioscience company, has been a topic of trend amongst traders and short sellers, who have seen its price take a beating a few months after its IPO last year.
The CEO (Mr. Au) has voiced his concerns that these negative sentiments are not only hurting the company but also investors and patients who are seeking treatments.
RGC’s business model is focused on using Traditional Chinese Medicine (TCM) to treat attention hyperactivity disorder ("ADD"
, autism spectrum disorder ("ASD" , and COVID-19-like illnesses, and these negative FUD (Fear, Uncertainty, and Doubt) are obstacles to the company’s mission and goal.
These negative sentiments are strategies deployed by sophisticated hedge funds by using short selling and complex derivatives to take advantage of small investors.
In defense against these strategic ploys by these hedge funds, Mr. Au has agreed to only draw $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserves share options for all employees except himself.
Furthermore, Mr. Au’s personal funds will be used to buyback company shares to demonstrate his commitment to the company and to reposition against short and distort sellers. Based on publicly available data, the company believes there is a total cumulative short volume of over 19 million shares since the company’s IPO.
Mr. Au "I began my share purchases last year, using my personal funds in order to further our goal of saving and improving lives."
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Regencell Bioscience Holdings (RGC), a healthcare bioscience company, has been a topic of trend amongst traders and short sellers, who have seen its price take a beating a few months after its IPO last year.
The CEO (Mr. Au) has voiced his concerns that these negative sentiments are not only hurting the company but also investors and patients who are seeking treatments.
RGC’s business model is focused on using Traditional Chinese Medicine (TCM) to treat attention hyperactivity disorder ("ADD"
, autism spectrum disorder ("ASD" , and COVID-19-like illnesses, and these negative FUD (Fear, Uncertainty, and Doubt) are obstacles to the company’s mission and goal. These negative sentiments are strategies deployed by sophisticated hedge funds by using short selling and complex derivatives to take advantage of small investors.
In defense against these strategic ploys by these hedge funds, Mr. Au has agreed to only draw $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserves share options for all employees except himself.
Furthermore, Mr. Au’s personal funds will be used to buyback company shares to demonstrate his commitment to the company and to reposition against short and distort sellers. Based on publicly available data, the company believes there is a total cumulative short volume of over 19 million shares since the company’s IPO.
Mr. Au "I began my share purchases last year, using my personal funds in order to further our goal of saving and improving lives."
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
